Johnson & Johnson expects details on Covid-19 vaccine trial next week

Johnson & Johnson also forecast 2021 adjusted profit of between $9.40 and $9.60 per share after its fourth-quarter sales rose to $22.48 billion from $20.75 billion

Reuters

26 January, 2021, 05:50 pm

Last modified: 26 January, 2021, 07:49 pm

Photo: Collected

Johnson & Johnson expects to share details on the company's late-stage Covid-19 vaccine trial early next week, Chief Executive Officer Alex Gorsky said at a post-earnings conference call on Tuesday

Data from Johnson & Johnson's single-dose Covid-19 shot was expected this month, with global hopes to battle the virus riding on multiple vaccines to ensure adequate supply.

In the latest setback to the effort, rival Merck & Co said on Monday it was discontinuing development of both its Covid-19 vaccines.

Johnson & Johnson also forecast 2021 adjusted profit of between $9.40 and $9.60 per share after its fourth-quarter sales rose to $22.48 billion from $20.75 billion.

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.